Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.51 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860856 | 0.88 | PPARD (0.48) | PPARDPPARA | |
| SCHEMBL5860930 | 0.84 | PPARA (0.41) | PTGER4PPARDSMN1; SMN2PPARANPC1 | |
| SCHEMBL5861723 | 0.83 | PPARD (0.66) | PTGER4PPARDPPARAPPARG | |
| SCHEMBL6164372 | 0.82 | PPARA (0.39) | PPARDSMN1; SMN2PPARAPPARG | |
| SCHEMBL5861754 | 0.81 | PTGER4 (0.53) | PTGER4PPARDPPARAPPARG | |
| SCHEMBL6162880 | 0.80 | PPARD (0.47) | PTGER4PPARDPPARA | |
| SCHEMBL5861943 | 0.79 | PPARA (0.50) | PTGER4PPARDPPARA | |
| SCHEMBL5860645 | 0.78 | NPC1 (0.44) | PPARDSMN1; SMN2PPARANPC1RAB9A | |
| SCHEMBL5860649 | 0.78 | NPC1 (0.44) | PPARDSMN1; SMN2PPARANPC1RAB9A | |
| SCHEMBL5862068 | 0.76 | PPARD (0.52) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091237-B2 | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1392674-B1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | PPARG, PPARD, PPARA | PTGER4 143/4885PPARD 2/4885SMN1; SMN2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.